1. Background {#s0005}
=============

Heart Diseases, including myocardial infarction (MI), are one of the leading causes of death in the world. They are responsible for approximately 30% of all cases of death around the world ([@bb0125]). According to data, around 10% of all patients with (MI) are under 45 years of age ([@bb0085]).

Almost 90% of (MI) cases are the result of an occlusive thrombosis in a coronary artery, occurring after the rupture of an atherosclerosis plaque ([@bb0260]). Consequently, a cascade of events follows: it begins with platelet aggregation, formation of thrombin and fibrin, and at last formation of the thrombus. Myocardial cells irrigated by the occluded artery will at a first time try to survive with a minimum of energy before dying, due to lack of oxygen ([@bb0245]).

In addition to known risk factors for (MI), such as arterial hypertension, smoking, hypercholesterolemia, obesity, diabetes, sedentary, and alcohol consummation, the genetic contribution to heart diseases has been proved ([@bb0260]). As being polygenic, these disorders involve the contribution of more than one gene; they are genes involved in the inflammatory (endothelial Nitric Oxide Synthase, eNOS), coagulation (plasminogen activating inhibitor, PAI) and lipid (APO lipoprotein A5, APOA5) pathways. Each one may act alone or in synergy with others. This makes the understanding of the genetic factors underlying these complex disorders as a very important challenge ([@bb0035]).

1.1. eNOS gene {#s0010}
--------------

Nitric Oxide (NO) is a molecule synthesized by endothelial cells; it contributes to vascular homeostasis and the regulation of several essential cardiovascular functions ([@bb0110]). NO is involved in vasodilatation process, regulation of blood pressure, and has numerous other vaso-protective and anti-atherosclerotic properties. Its production is controlled by endothelial Nitric Oxide Synthase (eNOS) gene; from [l]{.smallcaps}-arginine oxidation in vascular endothelium cells ([@bb0310]). The gene encoding eNOS is mapped on chromosome 7q35--36, and contains 26 exons and 25 introns ([@bb0060]). Several polymorphisms of eNOS gene have been reported. G894T variant, located in exon 7, is the most clinically relevant polymorphism in eNOS gene that has been described, and seems to be associated with reduced NO production, and development of coronary artery diseases (CAD), including (MI) ([@bb0075]).

1.2. PAI gene {#s0015}
-------------

The risk of thrombotic events can also be affected by variations in Plasminogen Activator Inhibitor type 1 activity (PAI-1) ([@bb0185]). This molecule belongs to the serpin family inhibitors and is one of the key inhibitors of plasmin generation in the plasma and tissues ([@bb0015]). It acts by inhibiting the activity of the fibrinolytic system, via inhibition of tPA (tissue plasminogen activator) and uPA (urokinase plasminogen activator). Localized on the chromosome 7, PAI-1 gene covers 16 Kb of longer and contains9 exons. It encodes for a protein of 50 KDa, composed by 379 amino acids ([@bb0015]). A single insertion/deletion of a "G" at position − 675 in the promoter region of the gene gives rise to 4G and 5G alleles, which differ by their regulation of PAI-1 activity ([@bb0230], [@bb0175]). Numerous studies have found an association between SNPs in PAI-1 gene and the development of many diseases (HTA, stroke...); concerning (MI), results remain contradictory ([@bb0080], [@bb0055], [@bb0320], [@bb0170], [@bb0225]).

1.3. APOA5 gene {#s0020}
---------------

High plasma level of TG is also one of the important risk factors of cardiovascular diseases. According to data, about 50% of the final levels are genetically determined ([@bb0100]). The influence of numerous gene polymorphisms on plasma TG levels has been intensively analyzed in last 15 years ([@bb0165]). The most promising results were connected with variants of the Apo-lipoprotein gene cluster APOA1/C3/A5. APOA was the last member to be discovered ([@bb0240]).

The Apo-lipoprotein A5 (APOA5) human gene is located on chromosome 11 (11q23), and consists of 4 exons. The protein encoded by this gene is composed by 369 amino acid ([@bb0240]). Many studies have demonstrated that APOA5 enhances the activity of the lipoprotein lipase (LPL), which leads to diminution of TG levels in VLDL particles ([@bb0120], [@bb0265]). Numerous variants of APOA5 gene have been detected ([@bb0240]). Two mutations of APOA5 gene, resulting in premature stop codons (Gln 145 and Gln 139), were found to have an effect on plasma TG levels, development of extreme hypertriglyceridemia, and development of myocardial infarction ([@bb0165]).

The main objective of our study is to investigate the potential association of + 894G/T, − 675 4G/5G and T1131C polymorphisms of the eNOS, PAI and APOA5 genes successively, with (MI) susceptibility, and to explore their frequencies, among Moroccan population.

2. Materials and methods {#s0025}
========================

2.1. Study population {#s0030}
---------------------

Blood samples were collected from 118 unrelated MI patients. The control group consisted of 184 unrelated and apparently healthy subjects showing no symptoms of coronary artery diseases. Clinical data concerning risk factors and biological parameters were collected for each patient in our study, and an informed consent was developed for both patients and controls.

2.2. DNA extraction {#s0035}
-------------------

Venous blood from all participants in this study was collected in tubes containing 3.2% sodium citrate. Samples were stored at − 20 °C until extraction of DNA. Genomic DNA was extracted from blood leukocytes using the standard method of salting out ([@bb0220]).

2.3. Genotype determination {#s0040}
---------------------------

We used PCR-RFLP to genotype samples for all + 894G/T eNOS, − 675 4G/5G PAI-1 and T1131C APOA5 polymorphisms, as previously described by ([@bb0145]), ([@bb0030]) and ([@bb0290]). Genotyping of each variant was performed by amplification from 50 to 100 ng of genomic DNA, followed by digestion using MboI restriction enzyme for + 894G/T eNOS, BslI for − 675 4G/5G PAI-1 and MseI for T1131C APOA5. For the + 894G/T eNOS polymorphism, digestion gave rise to three profiles: wild GG homozygous (one fragment of 206 bp), GT heterozygote (three fragments of 206, 119 and 87 bp), and mutated TT homozygous (two fragments of 119 and 87 bp). For the − 675 4G/5G PAI-1 polymorphism, profiles were: 4G/4G (one fragment of 98 bp), 4G/5G (three fragments of 98, 77 and 23 bp), and 5G/5G (two fragments of 77 and 23 bp). For the T1131C APOA5, profiles were: TT wild type (267 bp, 109 bp, 22 bp), TC (289 bp, 267 bp, 109 bp, 22 bp) and CC (289 bp, 109 bp). The digested products were separated on 3% agarose gel electrophoresis stained with Ethidium Bromide (BET), and visualized with UV rayons.

2.4. Statistical analysis {#s0045}
-------------------------

Statistical analysis was performed using SPSS 21.0 software. Chi square test (χ2) was used to determine statistical significance of association/non-association between genotypes and classical risk factors. Hardy--Weinberg Equilibrium test (HWE) was performed in both cases and controls groups for the 3 polymorphisms analyzed. Odd ratio (OR) was calculated to estimate the association between genotypes and MI risk, using a Confidence Interval (CI) of 95%. Significance was approved at P-value less than 0.05.

3. Results {#s0050}
==========

The distributions of G894T eNOS and T-1131C APOA5 variants were in accordance with Hardy--Weinberg equilibrium (HWE) among cases and controls. For the 4G/5G PAI-1 polymorphism, distribution was not in (HWE) in both cases and control groups ([Table 1](#t0005){ref-type="table"}). The average age of patients and controls was 56.27 ± 2 and 54.15 ± 2 respectively. Older age patients (age \> 50 years) were more frequents in our study sample compared to young subjects (age ≤ 50 years), with a predominance of males (73 male vs 45 female).

Risk factors analysis shows a positive correlation of G894T eNOS with sex and smoking. The T-1131C APOA5 variant was correlated with HTA and obesity; 4G/5G PAI-1 was not correlated with any one of the risk factors analyzed ([Table 2](#t0010){ref-type="table"}).

[Table 3](#t0015){ref-type="table"} reports the genotypic and allelic distribution of G894T eNOS, 4G/5G PAI-1 and T-1131C APOA5 polymorphisms, and their transmission models among cases and controls. For theG894T eNOS variant, genotypic frequencies were 50.85% GG, 62.37% GT and 6.78% TT, and 63.04% GG, 33.69% GT and 6.27% TT among cases and controls respectively. They were 7.64% 5G/5G, 57.62% 4G/5G and 34.74% 4G/4G, and 39.68% 5G/5G, 26.63% 4G/5G and 33.69% 4G/4G among cases and controls respectively for the 4G/5G PAI-1 variant; and 28.81% TT, 58.47% TC and 12.72% CC, and 51.08% TT, 40.21% TC and 8.71% CC among cases and controls respectively for the T-1131C APOA5 polymorphism. Allele frequencies of G894T eNOS variant were 72.03% G versus 27.97% T, and 79.89% G versus 20.11% T in cases and controls groups respectively. They were 36.45% 5G versus 63.55% 4G, and 52.98% 5G versus 47.02 4G among cases and controls respectively for the 4G/5G PAI-1 variant, and 58.05% T versus 41.95% C, and 71.19% T versus 28.81% C among cases and controls respectively for the T-1131C APOA5 polymorphism.

For G894T eNOS variant, a significant increase of risk of MI was observed in both GT (OR = 1.55, 95% CI = 0.97--2.48, P = 0.02) and TT (OR = 2.57, 95% CI = 0.87--7.52, P = 0.01) genotypes. There was a positive correlation of the 3 models with MI risk (dominant model: OR = 1.64, CI = 1.05--2.58, P = 0.003; recessive model: OR = 2.15, CI = 0.74--6.16, P = 0.03; additive model: OR = 1.54, CI = 1.06--2.23, P = 0.001) ([Table 3](#t0015){ref-type="table"}).

There was a significant correlation between 4G/4G and 4G/5G genotypes and MI risk (OR = 5.36, 95% CI = 3.8--7.2, P \< 0.001; OR = 11.2, 95% CI = 8.3--15.08, P \< 0.001 respectively). The dominant and additive models were significantly correlated to MI risk (OR = 7.96, 95% CI = 3.83--16.36, P = 0.01; OR = 1.96, 95% CI = 1.4--2.72, P = 0.01 respectively); yet the recessive model was not (OR = 1.04, 95% CI = 0.65--1.66, P = 0.8) ([Table 3](#t0015){ref-type="table"}).

For the T-1131C APOA5 variant, only the mutated genotype CC was correlated to MI risk (OR = 2.6, 95% CI = 1.18--5.66, P = 0.03 versus OR = 2.57, 95% CI = 1.56--4.17, P = 0.3 for the TC genotype). The recessive and additive models show a significant increase of MI risk (OR = 1.53, 95%CI = 0.72--3.2, P = 0.04; OR = 1.78, 95%CI = 1.26--2.51, P = 0.03 respectively); the association was not significant in the dominant model (OR = 2.58, 95% CI = 1.6--4.09, P = 0.07) ([Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0055}
=============

Myocardial infarction (MI) is a complex pathology, determined by numerous factors, including genetic. Several genes were found to be in association with MI susceptibility, they are genes involved in regulation of the vascular system, (eNOS gene), lipid-related pathways (APOA5 gene), fibrinolytic system (PAI gene), DNA repair pathways, renin angiotensin aldosterone system... ([@bb0325], [@bb0275], [@bb0130], [@bb0105], [@bb0115]). Our study is the first to explore the association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with myocardial infarction (MI) among a sample of Moroccan patients.

In our study sample, older aged patients (≥ 50 years) were more frequent than subjects \< 50 year of age, and most of them were male. This was in agreement with [@bb0085] study, reporting that about 90% of MI patients were \> 45 years of age.

4.1. eNOS {#s0060}
---------

Regarding its critical role in vascular system and blood flow regulation, NO--the main product of endothelial NOS enzyme--has been implicated in the occurrence of numerous pathologies, such as ischemic stroke ([@bb0070]), HTA ([@bb0295]), renal disease ([@bb0010]), and cardiovascular diseases ([@bb0050]). According to the literature, studies exploring the association of G894T eNOS polymorphism with MI predisposition still remain inconclusive and results are contradictory ([@bb0180]).

Concerning the association with risk factors, G894T eNOS polymorphism was significantly associated with sex and smoking ([Table 2](#t0010){ref-type="table"}). There was also a significant association of G894T eNOS genotypes and genetic models with MI risk ([Table 3](#t0015){ref-type="table"}). A meta-analysis performed by [@bb0180], involving 21,068 MI patients from 34 studies, also reported that there were significant association of eNOS G894T genotypes and the transmission models with MI risk: OR = 1.41 for TT genotype, OR = 1.12 for GT genotype, OR = 1.35 for the recessive model, and OR = 1.18 for the dominant model. In another study involving a sample of 323 CAD Tunisian patients, [@bb0025] reported that G894T eNOS polymorphism was associated with CAD under the dominant and additive models, but not the recessive one (additive OR: 2.81; 95% CI \[2.05--3.85\]; P \< 0.001, dominant OR: 2.84; 95% CI \[2.09--3.86\]; P \< 0.001, and recessive P = 0.09).

Several studies reported that carriers of the 894TT eNOS genotype have decrease of blood pressure comparing to those carrying the other genotypes. NO production-known for its role in regulation of blood pressure variability- is decreased and endothelial dysfunction occurs more often, leading to myocardial infarction development ([@bb0325], [@bb0275], [@bb0130], [@bb0105], [@bb0115], [@bb0070], [@bb0295], [@bb0010], [@bb0050], [@bb0180], [@bb0025], [@bb0040], [@bb0305], [@bb0255]).

Results relating eNOS G894T polymorphism to MI risk still remain conflicting and inconclusive. Many of them have found that G894T eNOS is associated to MI occurrence ([@bb0325], [@bb0280], [@bb0020], [@bb0145]). In their meta-analysis, [@bb0180] reported that subgroup analysis stratified according to ethnicity suggested that eNOS G894T variant was significantly correlated to MI susceptibility in the Asian subgroup with P \< 0.05 comparing to non-Asian subgroup (P \> 0.05). These findings suggest that ethnicity may explain some of the conflicting results related to the association between MI risk and G894T eNOS polymorphism, in addition to many other factors, such as differences of studies sample sizes; differences in selection of patients and controls.

4.2. PAI {#s0065}
--------

PAI-1 belongs to the serine proteinase inhibitor family, and is known for its role of regulating the endogenous fibrinolysis activity ([@bb0300]). Impaired fibrinolytic function, as being affected by increased plasma concentrations of PAI-1, is a marker of first and recurrent myocardial infarction, especially among young patients (\< 50 years of age) ([@bb0135], [@bb0140]).

The most studied polymorphism in PAI-1 gene is the insertion--deletion 4G/5G. Subjects homozygous for the 4G allele have PAI-1 plasma levels about 25% higher than those carrying double copy of the 5G allele ([@bb0090]). Available data investigating the potential association between 4G/5G PAI-1 polymorphism and myocardial infarction are inconclusive and provide divergent results ([@bb0195]).

Our results show that 4G/5G PAI-1 polymorphism was not associated with any one of the risk factors analyzed ([Table 2](#t0010){ref-type="table"}). We found that 4G allele was significantly associated with MI risk (P = 0.03), this risk became elevated among subjects carrying double copy of the 4G allele (5.36 fold higher) ([Table 3](#t0015){ref-type="table"}). Genetic dominant (4G/5G + 4G/4G vs 5G/5G) and additive (4G vs 5G) models were also significantly correlated to MI risk (OR = 7.96, 95% CI = 3.83--16.36, P = 0.01 and OR = 1.96, 95% CI = 1.4--2.72, P = 0.01respectively), but not the recessive model (OR = 1.04, 95% CI = 0.65--1.66, P = 0.8). In his meta-analysis, [@bb0195] reported similar findings concerning the association of the 4G allele with MI risk among a Chinese Han population; he reported that subjects carrying the 4G allele of the PAI-1 4G/5G gene in this population might be predisposed to develop coronary artery disease. Actually, the PAI-1 4G allele shows higher transcriptional activity than the 5G allele; this may explain why subjects homozygous for the 4G allele have elevated plasma PAI-1 concentrations and are more predisposed to thrombotic events such as myocardial infarction ([@bb0065]).

In a stratified analysis by ethnicity, [@bb0330] noted in his meta-analysis that Asians and Caucasians subjects carrying the 4G allele had higher risk of cardiovascular diseases, when [@bb0095] reported that the PAI 4G/5G genotype explained 0.63% of the variability of circulating PAI-1 levels in non-Hispanic whites, 0.99% in Hispanics, and 2.37% in blacks, and that there interaction analyses did not show any statistical differences in the relation between PAI-1 levels and the 4G/5G genotype by ethnicity.

Our study sample was not in HWG equilibrium for the distribution of 4G/5G PAI polymorphism among cases and controls (P = 0.003 and P \< 0.05 respectively). For that reason, we cannot say that the distribution in our sample study describes the real one of this variant among Moroccan MI patients. Thus, we cannot conclude about its association with MI risk among Moroccan MI patients.

4.3. APOA5 {#s0070}
----------

APOA5 is a good candidate for the investigation of Gene-cardiovascular diseases (CVD) risk association, as it enhances Lipo-Protein Lipase (LPL) activity and activates TG hydrolysis in the blood ([@bb0005], [@bb0215]). Increased plasma levels of triglycerides (TG) have always been considered as an important risk factor for (CVD) ([@bb0200], [@bb0100], [@bb0150]). Literature report that about 50% of their final levels are genetically determined ([@bb0165]). Numerous studies have reported a significant association between the T1131C APOA5 variant and cardiovascular diseases development, especially myocardial infarction (MI) ([@bb0155], [@bb0165], [@bb0160], [@bb0285], [@bb0335], [@bb0235]). However, this association was not observed in many other studies ([@bb0250], [@bb0210], [@bb0190]).

In our study, we found that T1131C APOA5 variant was associated with HTA and obesity. There was a significant association between the 1131C allele and MI risk (P = 0.03); among subjects carrying double copy of this allele, MI risk increases (2.6 fold higher) ([Table 3](#t0015){ref-type="table"}). These findings were in agreement with what Jing Xia et al. have found among a subgroup of Asian patients, but not among the European subgroup ([@bb0315]).

The distribution of genetic models shows an increase of MI risk under the recessive and additive models ([Table 3](#t0015){ref-type="table"}), but not the dominant one. In 2013, [@bb0205] performed a meta-analysis in which they combined the geographic distribution of APOA5 T1131Cvariant with different studies results, trying thereby to map a potential association of this polymorphism with CVD risk. Results of this study show that this variant was associated with CVD under the dominant, recessive and allelic models in both East Asia (P \< 10^− 5^) and India (P = 0.001), but not in Europe and Brazil (P = 0.17 and 0.613 respectively). In other Asian ethnic populations such as Korean and Chinese, an elevated prevalence of 1131C APOA5 allele was found (Ratio of the 1131C allele in cases/controls = 1.14 and 1.23 respectively), in contrast to Caucasians (Ratio of the 1131C allele in cases/controls = 1). There is a high prevalence of insulin resistance, CAD, pancreatitis... in these regions where a strong association exists ([@bb0045]), this may explain the heterogeneity of association found across these different geographic regions. All these findings support the idea of relating the inheritance of APOA5 T1131C variant to triglyceride increased levels and cardiovascular diseases risk, especially myocardial infarction ([@bb0270]).

The divergence of results between studies investigating the association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with MI risk can be explained by numerous factors such as studies sample sizes, differences of allele frequencies distribution among the studied populations, which may be as well affected by cultural reasons, eating habits... Also the ethnicity may explain a part of inconsistency between results found in literature ([@bb0205]). All these reasons and others may give rise to genetically differentiated populations, and automatically divergent results.

5. Conclusion {#s0075}
=============

Our study is the first to evaluate the association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with myocardial infarction risk among a sample of Moroccan patients. We found that eNOS G894T and APOA5 T1131C were significantly correlated to MI increased risk among Moroccan population. The PAI 4G/5G distribution was not in HWG equilibrium in cases and controls groups, so we cannot decide about its implication in MI susceptibility among MI Moroccan patients. Further studies including larger sample sizes and exploring interactions between these polymorphisms or between the genetic factor and biochemical parameters can provide useful information to better understand the susceptibility to MI and improve the biomedical context.AbbreviationsMImyocardial infarctioneNOSendothelial nitric oxide synthasePAIplasminogen activator inhibitorAPOA5Apo-lipoprotein A5CIconfidence intervalORodd ratioPCRpolymerase chain reactionRFLPrestriction fragment length polymorphism
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###### 

HWE equilibrium for the G894T eNOS, 4G/5G PAI and T1131C APOA5 distributions in cases and controls.

Table 1

                  EHW cases   EHW controls                                    
  --------------- ----------- ---------------------------------------- ------ ----------------------------------------
  G894T eNOS      0.32        0.85[\*](#tf0005){ref-type="table-fn"}   0.63   0.73[\*](#tf0005){ref-type="table-fn"}
  4G/5G PAI-1     7.03        0.003                                    44.8   \< 0.05
  T-1131C APOA5   4.73        0.09[\*](#tf0005){ref-type="table-fn"}   1.07   0.59[\*](#tf0005){ref-type="table-fn"}

Significant.

###### 

Distribution of G894T eNOS, 4G/5G PAI-1 and T-1131C APOA5 polymorphisms according to risk factors among MI patients.

Table 2

  Risk Factors   Patients N (%)   GG (%)      eNOS GT (%)   TT (%)     P-value   4G/4G (%)   PAI 4G/5G (%)   5G/5G (%)   P-value   TT (%)       APOA5 TC (%)   CC (%)      P-value
  -------------- ---------------- ----------- ------------- ---------- --------- ----------- --------------- ----------- --------- ------------ -------------- ----------- ---------
  Age            118                                                   0,07                                              0,8                                               0,38
   ≤ 50          34               12 (35,3)   18 (53)       4 (11,7)             13 (38,2)   18 (53)         3 (8,8)               7 (20,6)     23 (67,64)     4 (11,76)   
   \> 50         84               48 (57)     32 (38)       4 (5)                28 (33,3)   50 (59;5)       6 (7,2)               27 (32,14)   46 (54,76)     11 (13,1)   
  Sex            118                                                   0.01                                              0,1                                               0,44
   Male          73               32 (44)     38 (52)       3 (4)                22 (30,1)   43 (58,9)       8 (11)                22 (30,13)   44 (60,27)     7 (9,6)     
   Female        45               28 (62,2)   12 (26,7)     5 (11,1)             19 (42,2)   25 (55,6)       1 (2,2)               12 (26,7)    25 (55,6)      8 (17,7)    
  HTA            118                                                   0,26                                              0,09                                              0008
   presence      62               33 (55)     27 (54)       2 (25)               25 (61)     35 (51.5)       2 (22.2)              18 (52.9)    31 (44.9)      13 (86.7)   
   absence       56               27 (45)     23 (46)       6 (75)               16 (39)     33 (48.5)       7 (77.8)              16 (47.1)    38 (55.1)      2 (13.3)    
  Diabetes       118                                                   0,84                                              0,3                                               0,79
   presence      54               27 (45)     24 (48)       3 (37.5)             20 (48.8)   32 (47.1)       2 (22.2)              17 (50)      31 (44.9)      6 (40)      
   absence       64               33 (55)     26 (52)       5 (62.5)             21 (51.2)   36 (52.9)       7 (77.8)              17 (50)      38 (55.1)      9 (60)      
  Smoking        118                                                   0,04                                              0,39                                              0,76
   presence      49               19 (31.7)   29 (58)       1 (12.5)             14 (34.1)   30 (44.1)       5 (55.6)              15 (44.1)    29 (42)        5 (33.3)    
   absence       69               41 (68.3)   21 (42)       7 (87.5)             27 (65.9)   38 (55.9)       4 (44.4)              19 (55.9)    40 (58)        10 (66.7)   
  Obesity        118                                                   0,66                                              0,7                                               0.6
   presence      22               13 (21.7)   8 (16)        1 (15.5)             9 (22)      12 (17.6)       1 (11.1)              7 (20.6)     11 (15.9)      4 (26.7)    
   absence       96               47 (78.3)   42 (84)       7 (87.5)             32 (78)     56 (82.4)       8 (88.9)              27 (79.4)    58 (84.1)      11 (73.3)   
  Dyslipidemia   118                                                   0,37                                              0,34                                              0,88
   presence      34               16 (26.7)   17 (34)       1 (12.5)             11 (26.8)   22 (32.4)       1 (11.1)              9 (26.5)     20 (29)        5 (33.3)    
   absence       84               44 (73.3)   33 (66)       7 (87.5)             30 (73.2)   46 (67.6)       8 (88.9)              25 (73.5)    49 (71)        10 (66.7)   

###### 

G894T eNOS, 4G/5G PAI-1 and T-1131C APOA5 polymorphisms frequencies and genetic models among cases and controls.

Table 3

  -------------------------------------------------------------------------------------------
          Genotypes/alleles   Cases\        Controls\     OR (95% CI)            P-value
                              N = 118 (%)   N = 184 (%)                          
  ------- ------------------- ------------- ------------- ---------------------- ------------
  eNOS    GG                  60 (50,85)    116 (63,04)   1                      

          GT                  50 (42,37)    62 (33,69)    1,55 \[0,97; 2,48\]    0,02\*

          TT                  8 (6,78)      6 (3,27)      2,57 \[0,87; 7,52\]    0,01\*

          GG + GT^a^          110 (93,22)   178 (96,73)   1                      

          TT                  8 (6,78)      6 (3,27)      2,15 \[0,74; 6,16\]    0.03\*

          GG^b^               60 (50,85)    116 (63,04)   1                      

          GT + TT             58 (49,15)    68 (36,96)    1,64 \[1,05; 2,58\]    0.003\*

          G^c^                170 (72,03)   294 (79,89)   1                      

          T                   66 (27,97)    74 (20,11)    1,54 \[1,06; 2,23\]    0.001\*

  PAI     5G/5G               9 (7,64)      73 (39,68)    1                      

          4G/5G               68 (57,62)    49 (26,63)    11,2 \[8,3--15,08\]    \< 0.001\*

          4G/4G               41 (34,74)    62 (33,69)    5,36 \[3,8--7,2\]      \< 0.001\*

          4G/5G + 5G/5G^a^    77 (65,26)    122 (66,31)   1                      

          4G/4G               41 (34,74)    62 (33,69)    1,04 \[0,65--1,66\]    0.8

          5G/5G^b^            9 (7,64)      73 (39,68)    1                      

          4G/4G + 4G/5G       109 (92,37)   111 (60,32)   7,96 \[3,83--16,36\]   0.01\*

          5G^c^               86 (36,45)    195 (52,98)   1                      

          4G                  150 (63,55)   173 (47,02)   1,96 \[1,4--2,72\]     0.03\*

  APOA5   TT                  34 (28,81)    94 (51,08)    1                      

          TC                  69 (58,47)    74 (40,21)    2,57 \[1,56; 4,17\]    0,3

          CC                  15 (12,72)    16 (8,71)     2,60 \[1,18; 5,66\]    0,03\*

          TT + TC^a^          103 (87,28)   168 (91,29)   1                      

          CC                  15 (12,72)    16 (8,71)     1,53 \[0,72; 3,2\]     0.04\*

          TT^b^               34 (28,81)    94 (51,08)    1                      

          TC + CC             84 (71,18)    90 (48,91)    2,58 \[1,6; 4,09\]     0.07

          T^c^                137 (58,05)   262 (71,19)   1                      

          C                   99 (41,95)    106 (28,81)   1,78 \[1,26; 2,51\]    0.03\*
  -------------------------------------------------------------------------------------------

OR: Odds Ratio; CI: Confidence Interval; P value; \*: significant; N: Number; %: percentage; a: Recessive model; b: Dominant model; c: Additive model.

[^1]: Hind Hassani Idrissi and Wiam Hmimech contributed equally to this work.
